Related Experiment Video
Updated: Jan 3, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
A comprehensive evaluation of pathogenic mutations in primary cutaneous melanomas, including the identification of
Ivana Ticha1, Jan Hojny2, Romana Michalkova2
1Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic. ivana.ticha@vfn.cz.
Abstract:
The most common histological subtypes of cutaneous melanoma include superficial spreading and nodular melanoma. However, the spectrum of somatic mutations developed in those lesions and all potential druggable targets have not yet been fully elucidated. We present the results of a sequence capture NGS analysis of 114 primary nodular and superficial spreading melanomas identifying driver mutations using biostatistical, immunohistochemical and/or functional approach. The spectrum and frequency of pathogenic or likely pathogenic variants were identified across 54 evaluated genes, including 59 novel mutations, and the newly identified TP53 loss-of-function mutations p.(L194P) and p.(R280K). Frequently mutated genes most commonly affected the MAPK pathway, followed by chromatin remodeling, and cell cycle regulation. Frequent aberrations were also detected in the genes coding for proteins involved in DNA repair and the regulation and modification of cellular tight junctions. Furthermore, relatively frequent mutations were described in KDR and MET, which represent potential clinically important targets. Those results suggest that with the development of new therapeutic possibilities, not only BRAF testing, but complex molecular testing of cutaneous melanoma may become an integral part of the decision process concerning the treatment of patients with melanoma.
Insights
This study analyzed mutations in common melanoma types, identifying novel TP53 mutations and frequently altered genes in pathways like MAPK. Comprehensive molecular testing may guide future melanoma treatment decisions.
Area of Science:
- Oncology
- Genetics
- Dermatology
Background:
- Cutaneous melanoma, particularly superficial spreading and nodular subtypes, harbors a complex mutational landscape.
- Understanding the full spectrum of somatic mutations and potential therapeutic targets is crucial for effective treatment.
Purpose of the Study:
- To identify driver mutations and druggable targets in primary nodular and superficial spreading melanomas.
- To characterize the spectrum and frequency of pathogenic variants in key cancer-related genes.
Main Methods:
- Next-generation sequencing (NGS) using sequence capture on 114 primary melanomas.
- Biostatistical, immunohistochemical, and functional analyses to identify driver mutations.
- Evaluation of variants across 54 genes.
Main Results:
- Identified 59 novel mutations, including TP53 loss-of-function mutations p.(L194P) and p.(R280K).
- Frequently mutated genes involved MAPK pathway, chromatin remodeling, and cell cycle regulation.
- Detected aberrations in DNA repair, tight junction regulation, and identified KDR and MET as potential targets.
Conclusions:
- Complex molecular profiling, beyond BRAF testing, is essential for personalized melanoma treatment.
- Newly identified mutations and pathways offer potential therapeutic avenues for cutaneous melanoma.
More Related Videos
Related Concept Videos
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

